BioVie Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioVie Inc. (formerly NanoAntibiotics, Inc.) on March 24, 2017. The report covers a corporate governance event that occurred on March 14, 2017.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific corporate event and does not contain financial statements.
Material Changes
The material change reported is the election of a new independent director to the Board of Directors.
Management Commentary and Risks
The Board of Directors elected Julie Anderson as an independent member. Ms. Anderson is described as an experienced healthcare executive with specific expertise as a healthcare provider in the field of liver diseases. The filing notes that the biographical information provided is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Date of Director Election: March 14, 2017
- New Director: Julie Anderson
- Director Status: Independent Member
- Key Expertise: Healthcare provider specializing in liver diseases
- Company Former Name: NanoAntibiotics, Inc.